|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM105A |
Gene summary for FAM105A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM105A | Gene ID | 54491 |
| Gene name | OTU deubiquitinase with linear linkage specificity like | |
| Gene Alias | FAM105A | |
| Cytomap | 5p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NUU6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54491 | FAM105A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.40e-44 | 8.35e-01 | 0.294 |
| 54491 | FAM105A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.60e-16 | 1.14e+00 | 0.3487 |
| 54491 | FAM105A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.54e-19 | 4.74e-01 | 0.281 |
| 54491 | FAM105A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.40e-53 | 1.05e+00 | 0.3859 |
| 54491 | FAM105A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.26e-07 | 2.82e-01 | 0.2585 |
| 54491 | FAM105A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.05e-06 | 1.62e-01 | 0.3005 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM105A | SNV | Missense_Mutation | c.799N>G | p.Leu267Val | p.L267V | Q9NUU6 | protein_coding | deleterious(0.01) | benign(0.359) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
| FAM105A | insertion | Nonsense_Mutation | novel | c.823_824insGTTTGGGGCAACTATAAATAAAGTGGTTATAAAT | p.Glu275GlyfsTer6 | p.E275Gfs*6 | Q9NUU6 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| FAM105A | SNV | Missense_Mutation | c.382N>G | p.Lys128Glu | p.K128E | Q9NUU6 | protein_coding | tolerated(0.17) | probably_damaging(0.994) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FAM105A | SNV | Missense_Mutation | c.644N>T | p.Gly215Val | p.G215V | Q9NUU6 | protein_coding | tolerated(0.05) | possibly_damaging(0.564) | TCGA-AD-6901-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| FAM105A | SNV | Missense_Mutation | novel | c.838C>T | p.Pro280Ser | p.P280S | Q9NUU6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
| FAM105A | SNV | Missense_Mutation | rs200513203 | c.1016C>T | p.Pro339Leu | p.P339L | Q9NUU6 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FAM105A | SNV | Missense_Mutation | rs181133009 | c.877N>A | p.Asp293Asn | p.D293N | Q9NUU6 | protein_coding | tolerated(0.25) | probably_damaging(0.998) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| FAM105A | deletion | Frame_Shift_Del | novel | c.686delN | p.Ser231GlnfsTer13 | p.S231Qfs*13 | Q9NUU6 | protein_coding | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FAM105A | SNV | Missense_Mutation | novel | c.806N>A | p.Arg269Lys | p.R269K | Q9NUU6 | protein_coding | tolerated(0.36) | benign(0.058) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM105A | SNV | Missense_Mutation | rs769673611 | c.1036N>A | p.Glu346Lys | p.E346K | Q9NUU6 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |